Allergic rhinitis

- References

1-  Seidman MD, Gurgel RK, Lin SY, et al. AAO-HNSF. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43.

2-  Wise SK, Lin SY, Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis-executive summary. Int Forum Allergy Rhinol. 2018 Feb;8(2):85-107.

3-  de Groot H, Brand PL, Fokkens WF, et al. Allergic rhinoconjunctivitis in children. BMJ. 2007;335(7627):985-988.

4-  McCrory DC, Williams JW, Dolor RJ, et al. Management of allergic rhinitis in the working-age population. Evid Rep Technol Assess (Summ). 2003;(67):1-4.

5-  Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. Clin Exp Allergy. 2010;40(3):381-384. Dold S, Wjst M, von Mutius E, et al. Genetic risk for asthma, allergic rhinitis and atopic dermatitis. Arch Dis Child. 1992;67:1018.

6-  Wang DY. Risk factors of allergic rhinitis: genetic or environmental? Ther Clin Risk Manag. 2005;1(2):115.

7-  Bernstein LE, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3 suppl 3):S1-S148.

8-   Anon JB. Introduction to in vivo allergy testing. Otolaryngol Head Neck Surg. 1993;109(3 pt 2):593-600.

9-  40. Kim BJ, Mun SK. Objective measurements using the skin prick test in allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2010;136(11):1104-1106.

10-  Oppenheimer J, Nelson HS. Skin testing: a survey of allergists. Ann Allergy Asthma Immunol. 2006;96(1):19-23.

11-  Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67(1):18-24.

12-  Fornadley J, Corey J, Osguthorpe J, et al. Allergic rhinitis: clinical practice guideline. Otolaryngol Head Neck Surg. 1996;115(1):115-122.

13-  Krouse J, Mabry R. Skin testing for inhalant allergy 2003: current strategies. Otolaryngol Head Neck Surg. 2003;129(4 suppl):S33- S49.

14-  Sicherer SH, Wood RA. Allergy testing in childhood: using allergen-specific IgE tests. Pediatrics. 2012;129(1):193-197.

15-  Menardo JL, Bousquet J, Rodiere M, et al. Skin test reactivity in infancy. J Allergy Clin Immunol. 1985;75(6):646-651.

16-  Pearce MS, Salotti JA, Little MP, et al. Radiation exposure fromCT scans in childhood and subsequent risk of leukaemia and brain tumours. Lancet. 2012;380(9840):499-505.

17-  Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. Radiology. 1990;175:621-628.

18-  Sheikh A, Hurwitz B, Nurmatov U, et al. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010;(7):CD001563.

19-  Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2001;(4):CD001563.

20-   Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis: a systematic review of efficacy. Br J Gen Pract. 2003;53(489):318-322.

21-  Sheikh A, Hurwitz B, Shehata VA. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001563.

22-  Nurmatov U, van Schayk CP, Hurwitz B, et al. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012;67:158-165.

23-  Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med. 2003;349:237-246.

24-  Guagris S, Sazonov-Kocevar V, Thomas M. Burden of concomitant allergic rhinitis in adults with asthma. J Asthma. 2006;43(1):1-7.

25-   Kapsali T, Horowitz E, Diemer F, et al. Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol. 1997;99:S138.

26-  Erickson J, Berg A, Lotvall J, et al. Rhinitis phenotypes correlate with different symptom presentation and risk factor patterns of asthma. Respir Med. 2011;105:1611-1621.

27-  Boulay ME, Morin A, Laprise C, et al. Asthma and rhinitis: what is the relationship? Curr Opin Allergy Clin Immunol. 2012;12:449-454.

28-  Martin PE, Matheson MC, Gurrin L, et al. Childhood eczema and rhinitis predict atopic but not nonatopic asthma: a prospective cohort study over 4 decades. J Allergy Clin Immunol. 2011;127(6):1473-1479.

29-   Zeiger RS, Heller S. The development and risk of allergy in high risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol. 1995;95(6):1179-1190.

30-   Ricci G, Patrizi A, Baldi E, et al. Long term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol. 2006;55(5):765-771.

31-   Spergel JM. From atopic dermatitis to asthma, the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99-106.

32-   Bascom R, Wachs M, Naclerio RM, et al. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol. 1988;81:580.

33-   Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med. 1987;316:1506.

34-   Erin EM, Leaker BR, Zacharasiewicz AS, et al. Single dose topical corticosteroid inhibits IL-5 and IL13 in nasal lavage following grass pollen challenge. Allergy. 2005;60:1524-1529.

35-   Christodoulopoulos P, Cameron L, Durham S, et al. Molecular pathology of allergic disease, II: upper airway disease. J Allergy Clin Immunol. 2000;105:211.

36-  Meltzer EO, Jalowayski AA, Orgel A, et al. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol. 1998;102:39-49.

37-   Pipkorn U, Proud D, Lichtenstein LM, et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest. 1987;80(4):957-961.

38-  Baroody FM, Cruz AA, Lichtenstein LM, et al. Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. J Allergy Clin Immunol. 1992;90:373.

39-  Meyer P, Andersson M, Persson CG, et al. Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis. Pediatr Allergy Immunol. 2003;14:60-65.

40-   Mosges R, Konig V, Koberlein J. The effectiveness of modern antihistamines for treatment of allergic rhinitis—an IPD metaanalysis of 140,853 patients. Allergol Int. 2013;62:215-222.

41-  Tzanetos DB, Fahrenhol JM, Scott T, et al. Comparison of the sedating effects of levocetirizine and cetirizine: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2011;107(6):517-522.

42-  Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111(5):S835-S842.

43-  Day JH, Briscoe MP, Welsh A. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol. 1997;79(6):533-540.

44-  Kaiser HB, Goplan G, Chung W. Loratadine provides early symptom control in seasonal allergic rhinitis. Allergy Asthma Proc. 2008;29(6):654-658.

45-   Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther. 2000;22(6):760-769.

46-   Carlsen KH, Kramer J, Fagertun HE, et al. Loratadine and terfenadine in perennial allergic rhinitis: treatment of nonresponders to the one drug with the other drug. Allergy. 1993;48(6):431-436.

47-   Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79(6):507-511.

48-   Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med. 2010;104(5):615-625.

49-    Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and Desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006;22:151-157.

50-    Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2011;106:S6-S11.

51-   LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of Azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with Fexofenadine. Ann Allergy Asthma Immunol. 2004;93:154-159.

52-    Berger WE, White MV; Rhinitis Study Group. Efficacy of Azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol. 2003;91:205-211.

53-    Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol.

54-    Gonyeau MJ, Partisano AM. A clinical review of montelukast in the treatment of seasonal allergic rhinitis. Formulary. 2003;38:368-378.

55-  Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31:360-367.

56-   Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96:779-786.

57-  Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67:887-901.

58-  Cordray S, Harjo JB, Miner L. Comparison of intranasal hypertonic dead sea saline spray and intranasal aqueous triamcinolone spray in seasonal allergic rhinitis. Ear Nose Throat J. 2005; 84: 426–430.

59-   Rogkakou A, Guerra L, Massacane P, et al. Effects on symptoms and quality of life of hypertonic saline nasal spray added to antihistamine in persistent allergic rhinitis—a randomized controlled study. Eur Ann Allergy Clin Immunol. 2005; 37: 353–356.

60-  Ural A, Oktemer TK, Kizil Y, Ileri F, Uslu S. Impact of isotonic and hypertonic saline solutions on mucociliary activity in various nasal pathologies: clinical study. J Laryngol Otol. 2009; 123: 517–521.

61-  Chusakul S, Warathanasin S, Suksangpanya N, et al. Comparison of buffered and nonbuffered nasal saline irrigations in treating allergic rhinitis. Laryngoscope. 2013; 123: 53–56.

62-  Garavello W, Romagnoli M, Sordo L, Gaini RM, Di Berardino C, Angrisano A. Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: a randomized study. Pediatr Allergy Immunol. 2003; 14: 140–143.

63-  Garavello W, Di Berardino F, Romagnoli M, Sambataro G, Gaini RM. Nasal rinsing with hypertonic solution: an adjunctive treatment for pediatric seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol. 2005; 137: 310–314.

64-  Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, Mosges R. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2012; 26: e119–e125.

65-  Schwartz E. Oral hydrocortisone therapy in bronchial asthma and bay fever. J Allergy. 1954; 25: 112–119.

66-  Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol Tablets) for seasonal rhinitis: examination of dose and symptom response. J Clin Pharmacol. 1993; 33: 816–822.

67-  Kwaselow A, McLean J, Busse W, et al. A comparison of intranasal and oral flunisolide in the therapy of allergic rhinitis. Evidence for a topical effect. Allergy. 1985; 40: 363–367.

68-  Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids. Auris Nasus Larynx. 2013; 40: 277–281.

69-  Lejeune M, Lefebvre PP, Delvenne P, El-Shazly AE. Nasal sodium cromoglycate (Lomusol) modulates the early phase reaction of mild to moderate persistent allergic rhinitis in patients mono-sensitized to house dust mite: a preliminary study. Int Immunopharmacol. 2015; 26: 272–276.

70-  Tandon MK, Strahan EG. Double-blind crossover trial comparing beclomethasone dipropionate and sodium cromoglycate in perennial allergic rhinitis. Clin Allergy. 1980; 10: 459–462.

71-  McDowell MK, Spitz E. Treatment of chronic perennial allergic rhinitis: a double-blind trial of cromolyn sodium. Ann Allergy. 1977; 39: 169–174.

72-   Warland A, Kapstad B. The effect of disodium cromoglycate in perennial allergic rhinitis. A controlled clinical study. Acta Allergol. 1977; 32: 195–199.

73-   Kim KT, Kerwin E, Landwehr L, et al. Use of 0.06% ipratropium bromide nasal spray in children aged 2 to 5 years with rhinorrhea due to a common cold or allergies. Ann Allergy Asthma Immunol. 2005; 94: 73–79.

74-    Ensing K, de Zeeuw RA, Nossent GD, Koeter GH, Cornelissen PJ. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur J Clin Pharmacol. 1989; 36: 189–194.

75-   Dockhorn R, Aaronson D, Bronsky E, et al. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. Ann Allergy Asthma Immunol. 1999; 82: 349–359.

76-   Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009; 39: 271–279.

77-   Kopp MV, Hamelmann E, Bendiks M, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013; 24: 427–433.

78-   Chaker AM, Shamji MH, Dumitru FA, et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. J Allergy Clin Immunol. 2016; 137: 452–461.e9.

79-   Badorrek P, Dick M, Schauerte A, et al. A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis. Int J Clin Pharmacol Ther. 2009;47(2):71-77.

80-   Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324-332.

81-   Carr W, Bernstein JP, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1282-1289.

82-   Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(3):264-271.

83-   Benincasa C, Lloyd RS. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Investig. 1994;8:225-233.

84-   Nasser M, Fedorowicz Z, Aljufairi H, et al. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev. 2010;(7):CD006989.

85-   Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/ pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc. 2002;23(5):325-330.

86-   Grosclaude M, Mees K, Pinelli ME, et al. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology. 1997;35(2):67-73.

87-   Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995;96(2):139-147.

88-  Berkowitz RB, McCafferty F, Lutz C, et al. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies. Clin Ther. 2006;28(10):1658-1669.

89-    Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma. 2009;46(9):878-883.

90-   Ciebiada M, Barylski M, Gorska Ciebiada M. Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am J Rhinol Allergy. 2013;27(2):e58-e62.

91-  Watanasomsiri A, Poachanukoon O, Vichyanond P. Efficacy of montelukast and loratadine as treatment for allergic rhinitis in children. Asian Pac J Allergy Immunol. 2008;26(2-3):89-95.

92-   Nayak AS, Philip G, Lu S, et al. Montelukast Fall Rhinitis Investigator G. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88(6):592-600.

93-   Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001;31:61-68.

94-  Lombardo G, Quattrocchi P, Lombardo GR, et al. Concomitant levocetirizine and montelukast in the treatment of seasonal allergic rhinitis: influence on clinical symptoms. Italian Journal of Allergy and Clinical Immunology. 2006;16:63-68.

95-   Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917-922.

96-   Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259-267.

97-  Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(6):949-955.

98-  Saengpanich S, deTineo M, Naclerio RM, et al. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2003;129(5):557-562.

99-    Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol. 2010;32(9):669-674.

100-   Esteitie R, deTineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone proprionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010;105:155-161.

101-  Lau SK, Wei WI, Van Hasselt CA, et al. A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis. Asian Pac J Allergy Immunol. 1990;8(2): 109-115.

102-   Meltzer EO, Bernstein DI, Prenner BM, et al. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. Am J Rhinol Allergy. 2013;27(2):102-108.

103-   Baroody FM, Brown D, Gavanescu L, et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2011;127:927-934.

104-   Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126: 466–476.

105-   Bhargava S, Prakash A, Rehan HS, Gupta LK. Effect of systemic corticosteroids on serum apoptotic markers and quality of life in patients with asthma. Allergy Asthma Proc. 2015; 36: 275–282.

106-  Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59: 709–717.

107-  Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278-1288.

108-   Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;121:S1-S55.

109-   Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014;124(3):616-627.

110-   Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001936.

111-   Matricardi PM, Kuna P, Panetta V, et al. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol. 2011;128(4):791-799.

112-   Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003;(2):CD002893.

113-   Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740-752.

114-   Passali D, Passali FM, Damiani V, et al. Treatment of inferior turbinate hypertrophy: a randomized clinical trial. Ann Otol Rhinol Laryngol. 2003;112:683-688.

115-   Lee JY, Lee JD. Comparative study on the long-term effectiveness between coblation and microdebrider assisted partial turbinoplasty. Laryngoscope. 2006;116(5):729-734.

116-   Gunhan K, Unlu H, Yuceturk AV, et al. Intranasal steroids or radiofrequency turbinoplasty in persistent allergic rhinitis: effects on quality of life and objective parameters. Eur Arch Otorhinolaryngol. 2011;268(6):845-850.

117-   Mori S, Fujieda S, Yamada T, et al. Submucous turbinectomy decreases not only nasal stiffness but also sneezing and rhinorrhea in patients with perennial AR. Clin Exp Allergy. 1999;29(11):1542-1548.

118-    Chen K, Yu B. Certain progress of clinical research on Chinese integrative medicine. Chin Med J. 1999;112:934-937.

119-    Seidman MD, Grinsven GV. Complementary and integrative treatments: integrative care centers and hospitals: one center’s perspective. Otolaryngol Clin North Am. 2013;46(3):485-497.

120-    Xue CC, Li CG, Hugel HM, et al. Does acupuncture or Chinese herbal medicine have a role in the treatment of allergic rhinitis? Curr Opin Allergy Clin Immunol. 2006;6:175-179.

121-   Xue DD, Hugel HM, Li CG, et al. Efficacy, chemistry and pharmacology of Chinese herbal medicine for allergic rhinitis. Curr Med Chem. 2004;11:1403-1421.

122-    Brinkhaus B, Hummelsberger J, Kohnen R, et al. Acupuncture and Chinese herbal medicine in the treatment of patients with seasonal allergic rhinitis: a randomized-controlled clinical trial. Allergy. 2004;59:953-960.

123-   Hu G, Walls RS, Bass D, et al. The Chinese herbal formulation biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12 week clinical trial. Ann Allergy Asthma Immunol. 2002;88:478-487.

124-   Borchers AT, Hackman RM, Keen CL, et al. Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr. 1997;66:1303-1312.

125-   Latchman Y, Banerjee P, Poulter LW, et al. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). Int Arch Allergy Immunol. 1996;109:242-249.